ClinicalTrials.gg
Enrolling by invitationNCT02202681Updated Nov 10, 2026

Imaging the Duodenum Using an Optical Frequency Domain Imaging OFDI Capsule

An interventional study of OFDI Capsule in Celiac Disease and Healthy, sponsored by Massachusetts General Hospital. Enrolling by invitation at 1 site in United States. Open to participants aged 16 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Sep 2013, registered Jun 2014).
Updated Nov 10, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
108
Allocation
Not applicable
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 103 studies in Celiac Disease with a site in United States — 16 open to participants now, 20 under way, none of them phase 3. Celiac Disease · United States.

Planned enrollment
17th of 68
108 · median 46
Started
2013
with 6 others
No phase
26 of 103
5 open now
Primary completion
2028-10
later than 15 of 19 live
Registered
36th of 103
by date
Lead sponsor
5 of 103
Massachusetts General Hospital

Among the 103 studies in Celiac Disease with a site in United States, this one is the 17th largest by planned enrollment of the 68 interventional ones that give a count, is one of 7 that started in 2013, is one of 26 with no phase, reaches primary completion later than 15 of the 19 other live ones, and was the 36th registered.

Celiac Disease

353 studies on the registry are indexed under Celiac Disease; 78 are open to participants now.

Browse Celiac Disease studies →

Open to participants now

16 of the 103 studies in Celiac Disease with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 48 Celiac Disease studies recruiting now, 24 (50%) set no upper age limit and 19 (40%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 16 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 103 studies in Celiac Disease with a site in United States, or all of them as a file.
02

Study summary

The study is being done to assess the tolerability and feasibility of a tethered OFDI capsule to image the duodenum.

A total of 108 participants (36 healthy and 72 with clinically suspected or diagnosed Celiac disease) will be asked to swallow the tethered capsule, while they are awake and unsedated and ask for their feedback. Images will be taken using the OFDI system while the capsule travels from the esophagus into the stomach and into the duodenum.

Read the detailed description

Participants including healthy volunteers as well as patients with Celiac disease will be recruited and asked to swallow the OFDI capsule while being awake and unsedated. The capsule is attached to a tether which allows the operator to control as well as navigate the capsule as it progresses down the esophagus, through the stomach and into the duodenum using natural propulsive force called peristalsis.

As the capsule progresses, multiple 2-dimensional cross-sectional images of the duodenum are acquired. Images are analyzed at a later stage.

03

Conditions studied

  • Celiac Disease
  • Healthy

Browse trials for

Keywords

  • Duodenum
  • Optical Frequency Domain Imaging (OFDI)
  • Optical Coherence Tomography
  • Imaging
  • Celiac Disease
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be over 18 years for healthy volunteers
  • Participants must be over 16 years for patients with Celiac disease
  • Participant must be able to give

Exclusion criteria

Exclusion Criteria:

  • Participants with an inability to swallow pills or capsules.
  • Participants with esophageal or intestinal fistulas.
  • Participants with known esophageal or intestinal strictures resulting in a luminal diameter smaller than the diameter of the capsule.
  • Participants with a history of intestinal Crohn's disease.
  • Women who are pregnant.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
108 participants (estimated)

Study arms

  • Experimental
    OFDI Capsule Imaging

    Participant will swallow the OFDI Capsule and imaging will be performed using the OFDI system.

    Device: OFDI Capsule

Interventions

  • DeviceOFDI Capsule

    Imaging of the duodenum with the OFDI capsule and system

06

What researchers measure

Primary outcomes

  1. Tolerability of OFDI Imaging in subjects swallowing the OFDI capsule

    After participating in the study, the participant will be asked for feedback about tolerability of the procedure using a questionnaire.

    Time frame: Images will be acquired during the OFDI imaging session which should on average take anywhere from 30 minutes to 2 hours.

  2. Feasibility of OFDI Imaging in subjects swallowing the OFDI capsule

    An investigator will assess the quality of the recorded images and movies obtained with each exam after the imaging is completed.

    Time frame: Images will be acquired during the OFDI imaging session which should on average take anywhere from 30 minutes to 2 hours

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2013 (actual). Primary completion is estimated for Oct 2028, 181 months after the start.

Of 82 non-industry interventional studies with no phase under Celiac Disease, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 60. This study's planned 181 months is above that.

Counting every sponsor, half of 87 studies reached it within 27 months; a quarter within 12 and three quarters within 56.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Oct 2026 → Oct 2028 and completion Jul 2028 → Jul 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2014
First posted
Jul 29, 2014
StartActual
Sep 16, 2013
Primary completionEst.
Oct 28, 2028was Oct 2026
CompletionEst.
Jul 2030was Jul 2028
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 28, 2026→Oct 28, 2028
Nov 10, 2026
Study completion
Jul 2028→Jul 2030
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Primary completion Oct 28, 2026→Oct 28, 2028
    Study completion Jul 2028→Jul 2030
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT02202681
Responsible party
Guillermo Tearney (Principal Investigator, Massachusetts General Hospital) — Principal investigator
First posted
Jul 29, 2014
Start date
Sep 16, 2013
Primary completion
Oct 28, 2028 (estimated)
Completion
Jul 2030 (estimated)
Last update
Nov 10, 2026

Study contacts

Guillermo Tearney, MD., PhD
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion